Close

Vyvanse® Chewable Tablet added to Ontario Formulary

Vyvanse® (lisdexamfetamine dimesylate) chewable tablet will be publically reimbursed in Ontario for ADHD treatment from March 31, 2020 for individuals (6 years and older) who require 12-hour continuous coverage due to academic and/or psychosocial needs, under these circumstances: Patients demonstrate significant and problematic disruptive behaviour or who problems with inattention that interfere with learning; AND…